Understanding how a specific protein affects immune response in bladder cancer
Novel mechanism of chemokine nitration in bladder cancer
This study is looking at a protein called CCL2 and how changes to it might affect the immune system's ability to fight bladder cancer, with the hope that using a modified version of this protein could help improve treatment for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11083721 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called CCL2 in bladder cancer and how its modification may impact the immune system's ability to fight the disease. The study aims to explore how CCL2, which usually helps recruit immune cells to tumors, is altered in bladder cancer, potentially hindering effective treatment. By using a modified version of CCL2 that resists this alteration, researchers hope to enhance the immune response against bladder tumors. This could lead to better treatment strategies for patients with bladder cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bladder cancer who are seeking new treatment options.
Not a fit: Patients with non-cancerous bladder conditions or those who do not have bladder cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could improve the effectiveness of immunotherapy for bladder cancer patients.
How similar studies have performed: Previous research has shown promising results in enhancing immune responses through similar mechanisms, indicating potential for success in this approach.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Mukherjee, Neelam — University of Texas Hlth Science Center
- Study coordinator: Mukherjee, Neelam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.